Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration

Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Con...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Yannuzzi NA, Freund KB
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae288
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:60d4ac21e05c467fbf3ab94fb38ae288
record_format dspace
spelling oai:doaj.org-article:60d4ac21e05c467fbf3ab94fb38ae2882021-12-02T08:38:14ZBrolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration1177-5483https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae2882019-07-01T00:00:00Zhttps://www.dovepress.com/brolucizumab-evidence-to-date-in-the-treatment-of-neovascular-age-rela-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Consultants of New York, New York, NY, USA; 4Department of Ophthalmology, New York University School of Medicine, New York, NY, USAAbstract: Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation.Keywords: neovascular age-related macular degeneration, brolucizumab, vascular endothelial growth factor  Yannuzzi NAFreund KBDove Medical PressarticleNeovascular Age-Related Macular DegenerationBrolucizumabVascular Endothelial Growth FactorOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 13, Pp 1323-1329 (2019)
institution DOAJ
collection DOAJ
language EN
topic Neovascular Age-Related Macular Degeneration
Brolucizumab
Vascular Endothelial Growth Factor
Ophthalmology
RE1-994
spellingShingle Neovascular Age-Related Macular Degeneration
Brolucizumab
Vascular Endothelial Growth Factor
Ophthalmology
RE1-994
Yannuzzi NA
Freund KB
Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
description Nicolas A Yannuzzi,1 K Bailey Freund2–41Department of Ophthalmology, Bascom Palmer Eye Institute/University of Miami Miller School of Medicine, Miami, FL, USA; 2Luesther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, NY, USA; 3Vitreous Retina Macula Consultants of New York, New York, NY, USA; 4Department of Ophthalmology, New York University School of Medicine, New York, NY, USAAbstract: Age-related macular degeneration (AMD) is a global health concern and the leading cause of vision loss in the developed world. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy has revolutionized the treatment of neovascular AMD, but there are still challenges with delivery of care and treatment burden with currently available medications. Brolucizumab is a single-chain antibody fragment inhibitor of all isoforms of VEGF-A. Its small molecular weight allows for high solubility and tissue penetration. Brolucizumab has most recently been evaluated in 2 parallel phase 3 randomized controlled trials which demonstrated its safety and efficacy in an extended dosing regimen. The present review summarizes the safety, visual and anatomic outcomes, and durability of brolucizumab in the treatment of neovascular AMD and discusses some of the extended dosing regimens explored with currently approved medications and other therapies still under clinical investigation.Keywords: neovascular age-related macular degeneration, brolucizumab, vascular endothelial growth factor  
format article
author Yannuzzi NA
Freund KB
author_facet Yannuzzi NA
Freund KB
author_sort Yannuzzi NA
title Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
title_short Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
title_full Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
title_fullStr Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
title_full_unstemmed Brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
title_sort brolucizumab: evidence to date in the treatment of neovascular age-related macular degeneration
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/60d4ac21e05c467fbf3ab94fb38ae288
work_keys_str_mv AT yannuzzina brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration
AT freundkb brolucizumabevidencetodateinthetreatmentofneovascularagerelatedmaculardegeneration
_version_ 1718398419695828992